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Abstract
Background: Ovarian antibodies as detected by indirect immunofluorescence have been used to
detect ovarian autoimmunity, but to our knowledge the rate of false positive findings using this
method has never been reported.
Methods: Here we examine whether a commercially available ovarian antibody test system, using
cynomologous monkey ovary, might be useful in the diagnosis of autoimmune premature ovarian
failure. The test was performed in a blinded manner in 26 young women with 46,XX spontaneous
premature ovarian failure, in 26 control women with regular menstrual cycles (matched for age,
race, and parity) and 26 control men (matched for age and race). We also compared the frequency
of other autoantibodies associated with ovarian autoimmunity.
Results: As a group young women with premature ovarian failure had an increased incidence of
thyroid and gastric parietal cell autoimmunity (p < 0.05). Unexpectedly, however, nearly one third
(31%) of normal control women had ovarian antibodies using the commercially available test. One
half of young women with premature ovarian failure were found to have ovarian antibodies (P =
0.26). In our own laboratory we found similar results and we were unable to improve the specificity
of the test. None of 26 men were found to have ovarian antibodies (P < 0.001).
Conclusion: Since approximately one third of normal women were found to have ovarian
antibodies using the system under study, we conclude that ovarian antibodies as detected by this
indirect immunofluorescence method have poor specificity. The specificity of any ovarian antibody
test should be established before it is used clinically.
Background
Autoimmunity is a well-established mechanism of prema-
ture ovarian failure. [1–4]. It has been suggested that the
presence of ovarian antibodies may be helpful in the diag-
nosis of ovarian autoimmunity [5,6]. However, presently
there is no validated serum marker that can establish a di-
agnosis of autoimmune premature ovarian failure with
certainty [7]. Young women can experience ovarian failure
by several mechanisms other than autoimmunity [8]. A
false positive diagnostic test indicating autoimmunity as
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could put young women at risk for inappropriate therapy.
Such therapy could have serious consequences, such as
the development of osteonecrosis[4]
Some women with premature ovarian failure have ovari-
an follicles that function intermittently [9,10]. and preg-
nancies have occurred after the diagnosis of premature
ovarian failure [11–14]. Clinicians are in need of an accu-
rate method for the diagnosis of autoimmune oophoritis,
a test with proven sensitivity and specificity [15]. Here we
conduct an investigation to determine whether a commer-
cially available ovarian antibody test (Immunodiagnostic
Laboratories, Inc., San Leandro, CA) might be useful in
the diagnosis of autoimmune premature ovarian failure.
We performed the test in women with premature ovarian
failure, women with normal ovarian function, and in
men. We found that this commercially available test has a
high incidence of false positives. Therefore, this test would
not be expected to be useful in the diagnosis of autoim-
mune premature ovarian failure.
Methods
Patients and Controls
By local advertisement we recruited 26 control women
with regular menstrual cycles (matched for age and parity
to our patients) and 26 control men (matched for age).
The controls were also matched to patients for race. We re-
cruited patients with spontaneous premature ovarian fail-
ure by letters to physicians and notices in medical
journals. The National Institute of Child Health and Hu-
man Development Institutional Review Board approved
the protocol. We diagnosed premature ovarian failure in
women who before the age of 40 had experienced amen-
orrhea in association with serum FSH levels greater than
40 mIU/mL (confirmed on two separate occasions, at
least one month apart). Twenty-six patients with prema-
ture ovarian failure participated in this study (median age
of 33 years, range 18–39 years). The women had been di-
agnosed at a median age of 30 years (range 15–38 years).
The median time since diagnosis was 2 years (range 0.33–
12 years). All patients had a normal karyotype and had no
history of chemotherapy or radiation. Six patients (26%)
had hypothyroidism, one patient had Addison disease,
and one patient had Raynaud syndrome.
Ovarian Antibodies
We sent blinded specimens to Immunodiagnostic Labora-
tories, Inc. (San Leandro, CA) to be tested for ovarian an-
tibodies using an indirect immunofluorescence test
system supplied by Scimedx Inc. (Denville, NJ). The kit in-
cludes frozen sections of cynomologous monkey ovary as
tissue substrate, a positive control of human serum
known to contain antibodies against the zona pellucida, a
negative control serum, and fluorescein isothiocyanate
(FITC) conjugated goat antibodies against human immu-
noglobulins including IgG, IgM and IgA. Binding of anti-
body to the zona pellucida at a 1:10 dilution was reported
by the laboratory on a scale of 0 to 3+ according to the in-
tensity of fluorescence: 0, negative; 1+, weak; 2+ moderate
or 3+ strong fluorescence (Figure 1).
We also tested serum in our own laboratory using this
same test system (Scimedx, Inc., Denville, NJ). Aliquoted
serum samples of patients and controls were stored at -
80°C. After thawing at room temperature, serum samples
were diluted 1:10 with PBS. We confirmed the adequacy
of monkey ovary sections from individual lots in an un-
blinded manner before using them. For each experiment
slides of monkey ovary with the same lot number were al-
lowed to equilibrate to room temperature. Twenty micro-
liters of blinded sample were applied to the tissue
substrate slides. A slide containing positive and negative
controls was run unblinded with each experiment. Slides
were placed into a moist covered chamber and incubated
for 30 minutes at room temperature. Next, the slides were
washed in PBS for three 10-minute soaks. After blotting
the slides, 20 uL of FITC-conjugated goat antibodies
against human immunoglobulins was delivered to each
sample and slides were again incubated in the moist
chamber for 30 minutes. The washings and blotting were
repeated as above. Mounting medium and a coverslip
were applied. The slides were kept in a dark moist cham-
ber until evaluated using a Zeiss Axiophot Fluorescent Mi-
croscope (Carl Zeiss Inc., Thornwood, NY) at 40×
magnification with emission at 400 nM and excitation at
520–560 nM. We graded fluorescence of the zona pelluc-
ida on the same 0 to 3+ scale as noted above.
Reproducibility
To evaluate the reproducibility of the test we selected four
patient samples previously determined by this technique
to be 0, 1+, 2+, and 3+ for zona pellucida antibodies. In a
blinded manner, we tested each sample 15 times (5 tests
each on three separate days).
Other Autoantibodies
Antinuclear antibody (ANA) titer was determined by indi-
rect immunofluorescence using Hep-2 substrate. Rheu-
matoid factor was determined by latex agglutination.
Antiparietal cell antibodies were measured by indirect im-
munofluorescence using rat stomach (Smith Kline Bee-
cham Clinical Laboratories, Van Nuys, CA). Antithyroid
peroxidase (anti-TPO) binding activity was determined by
a radiobinding assay using Iodine125 labelled human re-
combinant thyroid peroxidase (Nichols Institute, San
Juan Capistano, CA).Page 2 of 7
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We used the Fischer exact test, chi-square, and the Spear-
man rank correlation test as appropriate. We used one-
tailed tests to look for an increase in autoantibody as com-
pared to controls and we set P < 0.05 as significant. Statis-
tical analysis was performed using Sigma Stat Software




Eight of 26 control women (31%) and 13 of 26 women
with spontaneous premature ovarian failure (50%) had
ovarian antibodies as detected by the commercial labora-
tory (Table 1). The frequencies were not significantly dif-
ferent (P = 0.26, chi-square test).
By our own laboratory
When we evaluated these same samples for ovarian anti-
bodies in our own laboratory we obtained similar results.
Twelve of 26 patients (46%) with premature ovarian fail-
ure had ovarian antibodies versus 10 of 26 control women
(38%) (P = 0.78, chi-square test; Table 1).
Reproducibility
We could not reliably reproduce the four categories of
ovarian antibody test grading. Although our results corre-
lated with the known graded samples (r = 0.72, P < 0.05),
the 1+ readings were reproduced in only 8 of the 15 tests
Figure 1
Indirect immunofluorescence using cynomologous monkey ovary. Shown are a representative sample of a positive 
control (A), a 3+ positive patient sample (B), and a negative control (C). The scale bar represents 50 µm. Each arrow points to 
a zona pellucida. Images were prepared in our laboratory using a commercially available test system (Scimedx, Inc., Denville, 
NJ).Page 3 of 7
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the 15 tests (13%) (Table 2). In contrast, the 0 and 3+
readings were reproduced in 13 (87%) and 12 (80%) of
the 15 respective tests (Table 2).
Efforts to improve the test
Because the 1+ and 2+ readings had poor reproducibility,
we were concerned that this inaccuracy might have im-
paired our ability to detect a difference between patients
and control women. We therefore redefined the outcome
measure to be read simply as positive (+) or negative (-).
Table 1: Results of ovarian antibody tests in women with premature ovarian failure (POF) and control women (CTRL) matched for age 
and parity.
Commerciala NIHb NIH Revised Methodc
Sample POF CTRL POF CTRL POF CTRL
1 1+ - 1+ 1+ + -
2 - - - 1+ - -
3 1+ 1+ 1+ 1+ + +
4 - - - 1+ - +
5 - 1+ - 2+ - +
6 - - - - - +
7 - 2+ 1+ 3+ + -
8 1+ - 1+ - + +
9 1+ - 2+ - + -
10 1+ - - - + -
11 1+ - 3+ - + +
12 - 1+ - - - -
13 - - - - - +
14 - 1+ - 1+ + -
15 1+ 1+ 1+ 2+ - -
16 - 1+ - - - +
17 - - - - - -
18 1+ - 1+ 2+ + +
19 1+ - 1+ - + -
20 - - - - - +
21 - 1+ - - - -
22 1+ - 1+ 1+ + -
23 1+ - - - - -
24 - - - - + -
25 2+ - 3+ - + +
26 1+ - 1+ - + -
Total (+) 13 8 12 10 14 11
aResults by commercial laboratory bResults by our laboratory using the commercial method cResults by our laboratory with outcome measure as 
simply positive (+) or negative (-)
Table 2: Reproducibility of the ovarian antibody grading system.
Known Graded Sample
0 1+ 2+ 3+
Test Result
0 13 6 2 2
1+ 1 8 2 0
2+ 1 1 2 1
3+ 0 0 9 12
Percent Reproduced 87 53 13 80Page 4 of 7
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orescence on the zona pellucida above background and
negative was defined as any fluorescence less than this.
Tests were then repeated using serum from the 26 patients
and 26 control women. We were unable to demonstrate a
significant difference using the revised outcome measure.
Patient serum was positive in 14 of 26 samples (54%) and
control serum was positive in 11 of 26 samples (42%)
(Table 1). When we tested the sera on three separate occa-
sions with this method, we found 9 patient sera (35%)
and 6 control sera (23%) to be consistently positive for
zona pellucida antibody (P = 0.38).
We were unable to improve the test by using higher dilu-
tions of serum (1:20, 1:40, and 1:80). All 26 patients and
all 26 controls were negative for ovarian antibodies at
1:20. The positive control sample was positive at 1:40 and
negative at 1:80.
Specificity
To evaluate the specificity of the test we compared sera
from 26 normal women with sera from 26 normal men
matched for age. The tests were performed at 1:10 dilution
using the positive and negative outcome measure as dis-
cussed above. Women were significantly more likely to
have ovarian antibodies than men. Eleven of 26 normal
women (42%) had ovarian antibodies whereas none of
the 26 normal men had these antibodies (P < 0.001).
These findings were confirmed in a separate experiment
(9/26 versus 0/26, P < 0.002).
Other Auto-antibodies
Results of other antibody tests are shown in Table 3.
Women with spontaneous premature ovarian failure were
significantly more likely than control women to have pa-
rietal cell antibodies (P < 0.05, Fischer's exact test) and
thyroid peroxidase antibodies (P < 0.05, Fischer's exact
test).
Discussion
There is evidence to suggest that some patients with spon-
taneous premature ovarian may have clinically significant
circulating ovarian antibodies. In a seminal study report-
ed in 1979, Coulam and Ryan demonstrated that patients
with premature ovarian failure, as a group, have ovarian
antibodies present in their sera as determined by immu-
noprecipitation of radiolabeled human ovarian proteins
[16]. However, the identity of these specific ovarian anti-
gen(s) remains unknown. It should pointed out, however,
that immunoblotting studies have failed to reveal a con-
sistent pattern of binding using the sera of patients with
premature ovarian failure[7].
Presently, there is no proven sensitive and specific serum
test to confirm that a woman has ovarian failure on an au-
toimmune basis[7]. Histologic evaluation of the ovary is
the only way to diagnose autoimmune oophoritis with
certainty [17]. Nonetheless, some clinicians currently use
commercial ovarian antibody tests for the diagnosis of au-
toimmune premature ovarian failure and make treatment
recommendations based on these findings. This approach
can have severe adverse consequences such as the devel-
opment of osteonecrosis related to glucocorticoid thera-
py[4]. Here we demonstrate that detection of ovarian
antibodies by indirect immunofluorescence using one
specific commercial test system has poor specificity as a
diagnostic test. The test is positive in nearly one-third of
normal women. Therefore, the test is not a useful diagnos-
tic marker of autoimmune premature ovarian failure.
We found that women with premature ovarian failure are
significantly more likely to have positive thyroid peroxi-
dase and parietal cell autoantibodies than women with
normal ovarian function. In this regard our findings are in
agreement with previous studies [18–20]. In contrast to
one previous study, however [21], we did not find a signif-
icantly higher prevalence of antinuclear antibodies in
women with premature ovarian failure.
Because little is known about the pathophysiology of hu-
man autoimmune oophoritis, experimental animal mod-
els have been used to gain insight into possible
mechanisms [22,23]. The fact that we found an increased
frequency of thyroid and gastric parietal cell antibodies in
our patients suggests similarity to a model of autoim-
mune ovarian failure that can be induced in certain strains
Table 3: Frequency of other selected autoantibodies in women with premature ovarian failure (POF) and control women matched for 
age and parity.
Antibody Test Women with POFa n = 26 Control Womena n = 26
Antithyroid peroxidase ≥ 0.9 u/mL 9 (35)b 3 (12)
Antiparietal Cell ≥ 1:10 4 (15)b 0 (0)
ANA ≥ 1:80 5 (19) 6 (23)
Rheumatoid Factor ≥ 1:320 2 (8) 0 (0)
aValues are the number of positive tests, in parentheses are percent positive bSignificantly different from controls (P < 0.05, Fischer's exact test).Page 5 of 7
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also develop autoimmunity against thyroid and gastric
parietal cells [22]. It is well established that these mice
with ovarian autoimmunity also develop circulating au-
toantibodies against the oocyte cytoplasm, the zona pellu-
cida, and against steroid producing cells [22]. While we
found evidence that one half of our patients had specific
antibodies directed against the zona pellucida, we did not
find any consistent pattern of immunofluorescence to
suggest that our patients had antibodies directed against
the oocyte cytoplasm or the steroid producing cells of the
ovary. It is noteworthy that immune serum from mice
with ovarian autoimmunity reacts specifically with an
oocyte-specific protein called MATER [24,25]. We have
subsequently identified the homologous human MATER
gene and protein[26] In ongoing work we are evaluating
the value of MATER antibodies as a marker for autoim-
mune ovarian failure in women.
The fact that we did not detect ovarian antibodies binding
to the zona pellucida in any of 26 men (p < 0.001) is in-
triguing. This finding supports proposals that pre-B cells
undergo positive selection directed by the presence of sur-
face heavy chains with low albeit sufficient affinity to the
autoantigen. It appears then, that men, lacking the specific
ovarian self-antigen, fail to provide positive selection for
these pre-B cells clones. Also, this finding suggests that the
detection system is specific for zona pellucida, and that
further refinement of the assay system by using pure hu-
man recombinant zona pellucida protein might be useful.
Sacco and Moghissi detected zona pellucida antibodies in
both men and women by indirect immunofluorescence,
but they used porcine rather than primate zonae pellici-
dae [27]. Normal animal and human serum are known to
contain a wide range of low-titer autoantibodies that have
been termed "natural autoantibodies" [28]. Even B cells
from newborn mice and human cord blood produce these
natural autoantibodies [29–31]. The low titer ovarian an-
tibodies that we demonstrate here in the serum of normal
women are likely natural autoantibodies, and not anti-
bodies with any pathophysiologic significance.
Identifying women with autoimmune premature ovarian
failure presents the opportunity to restore ovarian func-
tion by proper immune modulation therapy. However, at
present we don't really know how many women with pre-
mature ovarian failure develop it due to autoimmunity.
Currently, ovarian biopsy is the only way to diagnose au-
toimmune premature ovarian failure with certainty. How-
ever, because there is no treatment proven safe and
effective to restore fertility, in our view, ovarian biopsy is
not indicated outside a controlled trial [17].
Conclusions
We found that approximately one-third of women with
normal ovarian function have ovarian autoantibodies de-
tected by indirect immunofluorescence using monkey
ovary as substrate. Hence, this ovarian antibody test as
presently performed has poor specificity, and therefore
appears to have no benefit in the evaluation and manage-
ment of autoimmune premature ovarian failure. The spe-
cificity of any ovarian antibody test should be established
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